Anthropic Launches Internal Drug Discovery Program

Anthropic enters drug discovery to refine AI tools for pharma

Anthropic announced Tuesday it will launch an internal drug discovery program targeting diseases that traditional pharmaceutical companies typically ignore. The initiative aims to help the AI company better understand drugmakers' needs as it develops and sells AI tools through its Claude Science product.

Eric Kauderer-Abrams, Anthropic's life sciences head, revealed the program at a San Francisco event. He explained the company's rationale: building effective AI models for the pharmaceutical industry requires direct experience with the drug development process.

"We're doing this because we believe first and foremost that to build the right models, products and tools to accelerate the industry, we need to live it along with all of you," Kauderer-Abrams said. "We believe in the power of tight feedback loops, and there's no substitute for having our own experiences alongside you all in the trenches trying to develop drugs."

Focus on neglected diseases

The company will concentrate on treatments for conditions that lack commercial appeal for traditional biopharmaceutical firms. Anthropic's status as a public benefit corporation allows it to prioritize patient benefit over commercial returns, according to a company spokesperson.

Kauderer-Abrams did not specify what Anthropic would do with any promising drug candidates it discovers. Traditional pharmaceutical companies would typically advance such candidates into clinical trials, though Anthropic has not outlined its plans for that stage.

Jonah Cool, Anthropic's head of life sciences partnerships, emphasized that the drug discovery work supports the company's broader goal of creating and selling AI tools for life sciences companies.

Why it matters

Anthropic's move represents a strategic bet that hands-on drug discovery experience will produce better AI tools for pharmaceutical customers. By targeting neglected diseases, the company positions itself as mission-driven while gaining practical insights that could differentiate its Claude Science product from competitors. The approach also tests whether AI companies can succeed where tech giants like Alphabet and Apple have struggled to gain traction in healthcare, despite significant investments.

Tech's mixed healthcare record

The announcement places Anthropic among several technology companies attempting to crack the healthcare market. Alphabet and Apple have pursued various healthcare initiatives with mixed results. Amazon has built a more substantial presence through acquisitions, including One Medical and PillPack, now operating under Amazon Health Services.

The company said it is in the early stages of the program and will share more details as the work progresses.

These details were first reported by CNBC.